Citations

Clear

626 citation(s) found for "Mehta, SH".

Evaluating the heterogeneity of hippocampal avoidant whole brain radiotherapy treatment effect: A secondary analysis of NRG CC001
Cherng, H.R.R. , Bentzen, Søren M. , Armstrong, Terri S. , Gondi, Vinai , Brown, Paul D. , Mishra, Mark V. , Cherng, Hua-Ren R , Bentzen, Soren M , Armstrong, Terri S , Mishra, Mark V , Sun, Kai, Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | December 5, 2023 | Volume: 26 | Issue: 5 | Pages: 911-921

10.1093/neuonc/noad226 | PMID 38069666 Get It

Abstract Background Hippocampal avoidant whole brain radiotherapy (HA-WBRT) is the standard of care for patients needing WBRT for brain metastases. This study, using existing data from NRG Oncology CC001 including baseline tumor characteristics and patient-reported MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) scores, sought to identify subgroups of patients that demonstrate differential neuroprotective treatment response to HA-WBRT. Methods An exploratory analysis of NRG CC001, a phase 3 trial in which 518 patients were randomly assigned to WBRT plus memantine or HA-WBRT plus memantine, was performed. Rates of neurocognitive function failure (NCFF) were estimated between subgroups and stratified by arm. Covariate and subgroup interaction with differential treatment response were calculated. Results The benefit of HA-WBRT on decreasing NCFF was seen in patients living ≥ 4 months (HR 0.75, 95% CI: 0.58–0.97, P = .03), whereas patients living < 4 months derived no significant neurocognitive benefit. A significant association between baseline MDASI-BT cognitive factor and treatment response (interaction P = .03) was identified. Patients with lower MDASI-BT scores (less patient-reported cognitive impairment) derived significantly greater benefit (HR = 0.64, 95% CI: 0.48–0.85, P = .002) compared to those with highest MDASI-BT scores (HR = 1.24, 95% CI: 0.76–2.04, P = .39). Tumor histology also had a significant interaction (P = .01) with treatment response. Primary lung histology patients derived cognitive failure risk reduction (HR = 0.58, 95% CI: 0.43–0.77, P = .0007) from HA-WBRT, in contrast to nonlung primary histology patients (HR = 1.15, 95% CI: 0.78–1.50, P = .48). Conclusions Differential neuroprotective response to HA-WBRT was identified in this analysis. Patients surviving ≥ 4 months derived benefit from HA-WBRT. There is evidence of heterogeneity of treatment effect for patients with less severe patient-reported cognitive impairment at baseline and those with primary lung histology.
A Multicenter Real-World Analysis (RWA) of Primary Cutaneous Anaplastic Large Cell Lymphoma (PCALCL) Treated in the Modern Era
Jagadeesh, Deepa , Brammer, Jonathan E. , Wei, Wei , Chang, Julie , Montreh, Tavakkoli, Habib, Alma , Deshmukh, Yash, Macapagal, Sharina , Mehta–Shah, Neha , Barta, Stefan K , Mishra, Rahul , Watkins, Marcus P. , Iqbal, Madiha , Bennani, N. Nora , Lansigan, Frederick

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 6177-6177

10.1182/blood-2023-191176 Get It

Introduction: The real-world outcomes in patients (pts) with PCALCL in the era of targeted therapies like Brentuximab Vedotin (BV) is not well defined due to lack of large multicenter studies. We conducted a multicenter retrospective RWA to assess patient and disease characteristics, treatment patterns, survival outcomes and impact of novel therapies in this rare type of cutaneous T cell lymphoma (CTCL). Methods: A total of 95 adult (≥18 years) pts from 8 academic institutions in the United States diagnosed from 2010-2022 were included in the analysis. The study was approved by the Institutional Review Boards at the respective sites. Demographic and disease factors were summarized by descriptive statistics. Overall survival (OS) was estimated by Kaplan-Meier method and compared using log rank method. Results: In our cohort, the median age at diagnosis was 63 (range 18-93) years. The majority of pts were male 60%, white 79%, and had good performance status (PS) ECOG 0-1 (93%). Median time from initial presentation to diagnosis was 1.8 (range 0-211) months. Most common initial skin presentation was tumor 46% (44/95), followed by plaques 27% (26/95) and patches 15% (14/95). No pt presented with erythroderma. Median size of the largest lesion was 2 (range 0.5-20) cm. 63% had early stage (IA-IIA) disease and 86% had <5 skin lesions at the time of initial diagnosis. Furthermore, palpable lymph node (LN) (10%) and elevated LDH (18%) were uncommon at diagnosis. Initial treatments include localized radiation 60%, surgical excision 21% and topical steroids 11%. A small subset of pts received systemic treatments like CHOP 13% (12/95), BV 8% (8/95) and oral methotrexate 7% (7/95) as frontline therapy. A proportion of pts received XRT with CHOP (6/12) and BV (2/8). The overall response rate (ORR) to initial therapy was 68% (65/95) with 61% achieving a CR and 17% had primary refractory disease (stable and progressive disease). Relapse rate after 1st line therapy was 52% (49/95). In our cohort a total of 22 pts received BV after frontline therapy, of which 19 were BV naïve and 3 were re-treated. At the time of last follow up, 27% of our cohort were still on treatment, 78% were alive and 21% were dead; only 3% of deaths were attributed to the lymphoma. The median OS was 128 months (95% CI: 78.4-NA) (Figure 1) with a median follow up of 42 (range 0.5-123.5) months. The 5-year OS was 77%. On univariate analysis, older age (≥65 vs <65 years) (median OS 78 vs 128 months; p=0.004) and higher number of lesions (5-10 vs <5) (mOS 34 vs 128 months; p=<0.0001) were significant associated with OS (Table 1). Type and size of the skin lesions, presence of palpable LN, elevated LDH, stage, and treatment modalities had no impact on OS. Results of multivariate analysis will be presented at the conference. Conclusion: In this large multicenter RWA of PCALCL, excellent long-term survival was observed following frontline therapies that were mostly skin directed. The use of systemic therapies including BV were infrequent even in relapsed disease. Older age and increased number of skin lesions were associated with poor OS.
Patterns of Care and Impact of Initial Treatment in Peripheral T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (MER) Prospective Cohort Study
Ruan, Jia , Allen, Pamela B. , Cohen, Jonathon B. , Castillo, Luis Enrique Malpica , Mehta-Shah, Neha, Lossos, Izidore S. , Flowers, Christopher R. , Chen, Zhengming , Larson, Melissa C. , Bennani, N. Nora , Wallace, Danielle , Jaye, David L. , Vega, Francisco , Inghirami, Giorgio , Mou, Eric , Casulo, Carla , Mehta–Shah, Neha , Martin, Peter, Maurer, Matthew J. , Kahl, Brad S. , Cerhan, James R. , Feldman, Andrew L.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 3079-3079

10.1182/blood-2023-180318 Get It

Background Peripheral T-cell lymphomas (PTCLs) comprise a rare, heterogeneous group of non-Hodgkin lymphomas of mature T-cell origin. Most systemic (s) PTCL subtypes typically have poor outcomes with conventional anthracycline-based chemotherapy. Biomarker-driven and subtype-specific treatments are promising but unmet needs. Few benchmark studies exist to characterize the current real-world landscape of clinical and pathologic practice. We report the patterns of care and updated outcome data for PTCL patients enrolled in the LEO-MER multi-center prospective cohort study (ClinicalTrials.gov NCT02736357). Methods Patients aged 18 years or older with newly diagnosed PTCL were prospectively enrolled in the University of Iowa/Mayo Clinic MER cohort (2002-2015) or the expanded LEO cohort (2015-2020). Clinical, pathology, treatment, and outcome data were abstracted from medical records using a standard protocol in both cohorts. Pathology underwent expert re-review based on WHO criteria. Overall survival (OS) was calculated from date of diagnosis to date of death or last follow-up. Event-free survival (EFS) was calculated from date of diagnosis to disease progression, initiation of 2 nd line therapy, or death from any cause. EFS and OS were evaluated using Cox model and Kaplan-Meier estimator. Log-rank test was used to test the significance of difference between groups. Results LEO-MER enrolled 1132 PTCL patients during the study period (462 MER and 670 LEO). Of these, 722 were sPTCLs (281 MER and 441 LEO), including PTCL-NOS (N=253, 35%), anaplastic large cell lymphoma (ALCL; N=180, 24.9% [74 ALK+, 106 ALK-]), angioimmunoblastic T-cell lymphoma (AITL, N=164, 22.7%), extranodal NK-TCL (N=50, 6.9%), adult T-cell leukemia/lymphoma (N=33, 4.6%), enteropathy-associated TCL (N=19, 2.6%), and hepatosplenic TCL (N=13, 1.8%) ( Table 1). Median age at diagnosis was 60 years. M:F ratio was 1.5. Comparing LEO to MER, African American population was 15.4% vs 0.7%, and Hispanic was 10% vs 2.2%. Clinical characteristics were comparable between MER and LEO overall: PS≥2, 20.9%; elevated LDH, 50.7%; stage III-IV, 67.6%; and IPI 2-5, 65.7%. The most common 1 st line chemotherapy regimens overall were CHOP-based (N=506, 70%), including 60% receiving CHOP-like chemotherapy in both MER and LEO cohorts (CHOP [N=268, 37%], CHOEP [N=91, 13%] or EPOCH [N=75, 10%]), and 16% with CHOP-like in combination with novel agents in LEO cohort (BV+ [N=41, 9.3%], azacitidine+ [N=11, 2.5%], pralatrexate+ [N=10, 2.3%], lenalidomide+ [N=8, 1.9%]) ( Table 1). More patients received etoposide in LEO (40.3%) than in MER (20.3%). 74 patients (10.3%) underwent consolidative SCT following induction chemotherapy (71 auto and 3 allo). 65 patients (11.2%) received frontline therapy on clinical trials. At a median follow-up of 9.4 years in MER and 4 years in LEO, 177 (MER) and 269 (LEO) events, and 150 (MER) and 206 (LEO) deaths were observed, respectively. The 3-year EFS and 4-year OS estimates for sPTCL were 46.3% and 59.1% in MER, and 40.4% and 51.3% in LEO. EFS and OS correlated with IPI scores and differed by sPTCL subtypes ( Figure 1). ALCL had superior survival, with 3-year EFS and 4-year OS of 78.2% and 90.5% for ALK+, and 65.9% and 76.9% for ALK-. Non-ALCL subtypes including PTCL-NOS and AITL had inferior outcomes, with 3-year EFS and 4-year OS of 31.4% and 42.8% for PTCL-NOS, and 33.4% and 50.7% for AITL. In subset analysis, the addition of etoposide to CHOP chemotherapy as either CHOEP or EPOCH was associated with improved OS for ALK- ALCL (p=0.038, log-rank), but not for ALK+ ALCL (p=0.75) or non-ALCL subtypes of PTCL-NOS and AITL (p=0.88). Conclusion The LEO-MER study is the largest prospective cohort study of PTCL to date. Patterns of care in the LEO cohort begin to incorporate novel agents in frontline therapy. Outcomes continue to mature with longitudinal follow-up and ongoing accrual, which poise to shape benchmarks in the contemporary era. The lack of benefit of etoposide adding to CHOP induction and poor overall survival of non-ALCL subtypes underscores the unmet need of therapeutic breakthrough for non-ALCL frontline treatment, particularly through clinical trials with biomarker-guided approaches incorporating novel agents.
Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)
Ansell, Stephen M. , Mehta–Shah, Neha , Amengual, Jennifer E. , Cole, Peter D. , David, Kevin A. , Advani, Ranjana H. , Ambinder, Richard F. , Thomas, Sachdev , Advani, Ranjana H , Ambinder, Richard F , Diefenbach, Catherine , Jegede, Opeyemi A. , Steidl, Christian , Natkunam, Yasodha , Scott, David W. , Forlenza, Christopher J. , Bartlett, Nancy L. , Ibrahimi, Sami , Kahl, Brad S.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 607-607

10.1182/blood-2023-184531 Get It

Background: Relapsed/refractory (R/R) Classic Hodgkin lymphoma (cHL) remains a significant clinical challenge. We hypothesized that using immune checkpoint blockade to activate the immune cells in the tumor microenvironment, and concurrently targeting tumor cells with the CD30 targeting antibody-drug conjugate brentuximab vedotin (BV) could overcome tumor resistance. E4412 is an intergroup Phase 1/2 ECOG-ACRIN sponsored study of the combinations of BV, nivolumab (N), and ipilimumab (I) in patients with R/R cHL. Here we present the efficacy and safety data on the full adult cohort of patients treated in Phase 2 randomized between BV/N and BV/N/I. Methods: Patients with confirmed R/R cHL were randomized between the doublet of BV/N with BV 1.8mg/kg and N 3mg/kg and BV/N/I with I 1mg/kg. BV and N were administered every 3 weeks, and I every 12 weeks for up to 1 year for BV and up to 2 years for N and I. Results: One hundred twenty-six patients were enrolled and treated; 8 patients (4 from each arm) were excluded from efficacy analysis based on ineligibility. Patients were not heavily pretreated, 65% had one prior line of therapy and an additional 27% had two prior lines, and 8% had more than 2 prior lines. The median age was 34; 51% of patients were male. Sixteen patients had prior BV: 10 (BV/N arm) and 6 (BV/N/I). Response: One hundred eighteen patients are evaluable for response: 61 treated with BV/N and 57 with BV/N/I. With BV/N 37 of 61 (60.7%) of patients had a complete response (CR) compared to 38 of 57 (66.7%) with BV/N/I for a difference of 6.7% (p-value 0.31). Additionally, 17 (28%) with BV/N and 12 (21%) of patients treated with BN/N/I had a partial response (PR) for an overall response rate (ORR) of 88% in both arms. In a planned analysis of patients with prior treatment with BV the CR rate was 25% in BV/N arm (2 of 8) and 60% in BV/N/I arm (3 of 5). The median follow-up for progression free survival (PFS), duration of response (DOR), and overall survival (OS) is 24.8 months and 33.7 months. The median PFS, duration of response and OS have not been reached for either arm with 24 months of follow-up ( Figure 1). In B/N 30 of 61 patients came off study to receive alternative treatments (primarily autologous stem cell transplant (SCT)) and in BV/N/I 23 of 57 patients did. Safety: Table 1 shows treatment-related Grade 3+ toxicity occurring in > 1 patient and adverse events (AE) of special interest. All 126 patients (118 eligible and 8 ineligible) are evaluable for safety. The rate of Grade 3+ treatment related toxicity is 43% (28/65) and 52% (32/61) for BV/N and BV/N/I, respectively. However, when rash is excluded the rate of treatment related toxicities is similar between the two arms 38.5% vs 39.3%. There was no grade 4 rash, and the rash was treatable in all cases with topical or oral steroids. There were no Grade 5 toxicities in either arm. Conclusion: In this randomized Phase 2 study comparing BV/N vs. BV/ N/I the difference in CR rate of 6.7% between the doublet and the triplet was not statistically significant. Additionally, the triplet had more grade 3 rash than the doublet, there was otherwise no significant difference in grade 3 or greater toxicity between the two arms. With a median follow-up of 24 months the PFS and DOR have not been reached for either arm, suggesting excellent disease control from both regimens. Differences in response for BV pre-treated patients between the two arms is intriguing especially as more patients are treated with BV in the frontline, but the sample size is too small to draw firm conclusions. Correlative studies are underway to elucidate a response vs. resistance signature, and biological understanding of differential benefit.
Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy
Kumar, Anita , Joseph, Ashlee , Hill, Brian T. , Maddocks, Kami J. , Danilov, Alexey V. , McCarthy, Christine , Ruan, Jia , Nizamuddin, Imran , Khan, Nazneen B., Ouchveridze, Evguenia, Young, Philip, Portell, Craig A. , Harris, Zoey I., Pongas, Georgio, Lossos, Izidore S. , Baidoun, Firas, Gerber, Drew G. , Greenwell, Irl Brian , Stack, Anthony C., Messmer, Marcus , Narkhede, Mayur , Wang, Michael , Moyo, Tamara K. , Anna, Jacob, Stanisic, Alexander V., Kugathasan, Laveniya , Villa, Diego , Cohen, Jonathon B. , Martin, Peter , Stanisic, Alexander , Brooks, Taylor R , Portell, Craig A , Stanisic, Alexander V , Wang, Yucai , Larson, Melissa C. , Hwang, Steven R. , Brooks, Taylor , Bond, David A. , Kahl, Brad S. , Grover, Natalie S. , Ouchveridze, Evguenia, Tun, Aung M. , Muñoz, Javier , Reagan, Patrick Michael , Ryan, Christine E. , Merryman, Reid W. , Baidoun, Firas , Moustafa, Muhamad Alhaj , Ayyappan, Sabarish Ram , Link, Brian K. , Velayati, Arash , Banaszak, Lauren Gabriele , Pophali, Priyanka A. , Stack, Anthony , Mehta, Amitkumar , Jain, Preetesh , Ghosh, Nilanjan , Bhansali, Rahul S. , Barta, Stefan K , Kamdar, Manali , Karmali, Reem , Maurer, Matthew J. , Cerhan, James R.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 300-300

10.1182/blood-2023-182942 Get It

Background: Bendamustine and rituximab (BR) is a standard-of-care first-line (1L) therapy for older or unfit patients with mantle cell lymphoma (MCL). The SHINE trial compared BR with rituximab maintenance plus ibrutinib vs placebo in patients ≥65 years old and showed that the ibrutinib arm had significantly improved progression-free survival (PFS; median 80.6 vs 52.9 months) but similar overall survival (OS; 57% vs 55% at 7 years) compared to the placebo arm. Whether sequential treatment with BR in 1L and a Bruton's tyrosine kinase inhibitor (BTKi) in second-line (2L) can result in a similar cumulative PFS compared to 1L BR plus BTKi combination therapy is unknown. To provide insight to this question, we modeled observational data to evaluate MCL outcomes after 1L BR and 2L BTKi therapy in the BTKi era. Methods: Patients with MCL who received 1L BR with or without rituximab maintenance in 2014-2020 at one of the 27 participating centers were included. Exclusion criteria included participation in the SHINE or ECHO trials, any additional 1L therapy other than BR (with or without rituximab maintenance), and stem cell transplant consolidation after 1L BR. Baseline characteristics, treatment, and follow-up data were abstracted by chart review. Event-free survival (EFS) was defined as time from index line treatment start to the first event (progression, relapse, retreatment, or death). OS was defined as time from index line treatment start to death. Using an intention-to-treat (ITT) framework, EFS2 was defined as time from 1L BR start to progression, relapse, or retreatment following 2L BTKi treatment or death. Patients who received a non-BTKi treatment at 2L were censored for EFS2 at 2L treatment start; living patients without an event following 1L BR or 2L BTKi were censored for EFS2 at last follow-up. Results: A total of 618 patients with MCL who received 1L BR in 2014-2020 were included. The median age was 71 (IQR 65-76) years, and 447 (72%) were male. 59 (11%) patients had an ECOG PS ≥2, 566 (93%) had stage III-IV disease, and simplified MIPI was low in 105 (21%), intermediate in 200 (39%), and high in 202 (40%) patients. The median follow-up following 1L BR start was 57.4 (95% CI 53.8-63.2) months. Response data were available in 580 patients, and the best ORR was 92% (79% complete response [CR] and 13% partial response [PR]). 258 (42%) patients received rituximab maintenance. As of last follow-up, 255 patients were alive and in remission after 1L BR, 92 patients died without 2L therapy, and 271 patients received a 2L therapy. The median EFS was 34.1 (95% CI 31.0-40.0) months. The median OS was 97.8 (95% CI 81.2-NA) months, the 5-year OS rate was 58.6% (95% CI 54.4-63.2), and the 7-year OS rate was 56.7% (95% CI 52.4-61.5) (Fig 1). Among the 271 patients who started a 2L treatment, 203 (75%) received a BTKi at 2L - 101 (50%) ibrutinib, 76 (37%) acalabrutinib, and 26 (13%) zanubrutinib. The median follow-up following 2L BTKi start was 38.5 (95% CI 31.3-45.1) months. Response data were available in 171 patients, and the best ORR was 64% (36% CR, 28% PR). The median EFS was 10.7 (95% CI 7.7-14.0) months, and the median OS was 24.8 (95% CI 17.3-33.1) months with 2L BTKi therapy (Fig 2). By ITT analysis, the median EFS2 following 1L BR and 2L BTKi was 72.1 (95% CI 56.7-97.8) months (Fig 1). A subset analysis of patients aged ≥65 years (n=471; 198 [42%] received rituximab maintenance) showed similar results. The median EFS with 1L BR was 32.7 (95% CI 29.1-36.3) months. The median OS was 81.5 (95% CI 65.0-NA) months, and the 7-year OS rate was 53.3% (95% CI 48.3-58.7). 208 patients received a 2L therapy, 163 (79%) with a BTKi. The median EFS was 11.5 (95% CI 7.6-15.8) months, and the median OS was 21.0 (95% CI 14.0-29.6) months with 2L BTKi therapy. By ITT analysis, the median EFS2 following 1L BR and 2L BTKi was 58.0 (95% CI 50.2-77.0) months. Conclusion: In this multicenter retrospective study, initiation of 1L BR (with or without rituximab maintenance) resulted in a 7-year OS of 57%. Median EFS2 for sequential 1L BR and 2L BTKi was 72.1 months. In context, the SHINE study reported a median PFS of 80.6 months in the BR (with rituximab maintenance) plus ibrutinib arm and a 7-year OS of 57% in the ibrutinib arm and 55% in the placebo arm, where 39% of patients received a BTKi in 2L. Within the constraints of observational data, our results provide support for sequential use of BR in 1L and BTKi in 2L for patients with MCL.
1391. "Going Viral for Good: The Global Impact of #IDTwitter in the Infectious Diseases Twitter Community"
Mehta, Priyal , Padte, Smitesh , Mahendru, Diksha , Tawfeeq, Sawsan , Arshad, Zara , Atanasov, Atanas G. , Kashyap, Rahul , Nawaz, Faisal A.

Mayo Clinic

Open Forum Infectious Diseases | November 27, 2023 | Volume: 10 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofad500.1228 Get It

Abstract Background Twitter has become an invaluable resource for gaining insights into crucial developments in global healthcare communication. The hashtags (#) can be used to categorize tweets and gather conversations on a specific topic or to target a particular audience. Although the prevailing knowledge fund underlines the potential of digital networks to essentially influence the management of infectious diseases (ID), there has been no comprehensive analysis on the user information in the ID Twitter community, nor of the influence this hashtag has generated. The objective of our study was to evaluate the demographic data of #IDTwitter users, discern the most influential members and popular narratives in this realm, and ascertain the impact of the hashtag. Methods Using data from 28th June 2019 and 28th March 2023, an extensive analysis was conducted using the Symplur Signals research analytics tool. The analysis focused on the cumulative number of tweets, impressions, and unique users who shared tweets containing the hashtag #IDTwitter, with users categorized into specific healthcare stakeholder groups. The primary outcome measures were outreach and awareness measured by the number of tweets and impressions. Results The study observed the trends of #IDTwitter over a period of 45 months and found 441,650 tweets were shared by 92,734 users that generated a total of 1,833,037,732 impressions (views). Top five co-occurring hashtags were #IDtwitter, #MedTwitter, #MedEd, #COVID19, #TwitteRx. The top five countries reporting the greatest number of users of this hashtag were The United States of America (48326), Canada (4803), Mexico (3413), India (2759), Australia (2658). Various healthcare stakeholders’ categories were identified and three largest groups of contributors were Doctors (14.55%), Healthcare Providers (7.54%) and Researcher/Academic (3.70%). The top three influencers of this hashtag include two clinical pharmacists and one organization account. Country-wise distribution of Users of #IDTwitter The image shows the geographical distribution of the users who posted tweets containing #IDTwitter were shared (based on the locations at which the posting accounts were registered). Twitter is used worldwide for conversations regarding communicable diseases and their prevention, not only among the general public but also among students and professionals via online chat discussions and virtual rounds. Stakeholders of #IDTwitter Accounting for the percentage distribution of #IDTwitter-posting users in various healthcare stakeholders categories (data derived from Symplur Signals, with the classification being based on information provided in the Twitter biographies of the users- https://help.symplur.com/en/articles/103684-healthcare-stakeholder-segmentation). Twitter has become a quintessential tool for connecting people worldwide, and we can leverage this platform to our advantage by paying close attention to the topic and content of hashtag exchanges to combat misinformation related to matters like antibiotic usage or any epidemic infection on social media platforms. Top Co-occurring Hashtags The hashtags that generally appear alongside of #IDTwitter could provide an insight regarding the popular discussions involving #IDTwitter. Conclusion Our findings indicate that there is considerable interest in using #IDTwitter to promote relevant content and engage a geographically diverse audience. It underscores the vitality of professional voices in combating misinformation and we could definitely leverage this 'viral' hashtag for our advantage. Disclosures All Authors: No reported disclosures
STEM-15. STAT5-OLIG2 TRANSCRIPTIONAL COMPLEX MEDIATES GLIOMA STEM CELL SELF RENEWAL AND INVASION
Miller, Aunay , Cascio, Costanza Lo , Blomquist, Mylan, McNamara, James, Orndorff, Keely, Dufault, Matthew , Sereduk, Christopher, Loftus, Joseph C. , Mehta, Shwetal , Orndorff, Keely, Sereduk, Chris , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v35-v36

10.1093/neuonc/noad179.0140 Get It

Abstract Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, despite current treatment options. One of the major contributing factors to this dismal outcome is a subset of cells called glioma stem cells (GSCs) that are highly tumorigenic, invasive, and resistant to conventional treatments. Thus, studies that focus on the properties of GSC biology are needed to develop novel therapies to improve overall survival. Here we report a novel role of STAT5 in GSC stemness and survival. In GBM tumors, STAT5 has been shown to be active in the infiltrative, residual population of cells remaining post-surgery. Knockdown of STAT5 results in the decrease in GSC stemness and therapeutic resistance. Interestingly, we find that expression of OLIG2, a key cell fate factor important for the tumorigenic potential of GSCs, affects STAT5 activation with a positive correlation between OLIG2 and STAT5 mRNA expression in GBM tumors. Furthermore, we find that in GSCs expressing EGFRvIII, STAT5 interacts with OLIG2 and pharmacological inhibition of STAT5 activation or knockdown of STAT5 expression results in decrease of OLIG2-mediated GSC invasion. Together, these data suggest a novel transcriptional complex, STAT5-OLIG2, in the potential role for GSC survival, maintenance, and invasion.
QOL-18. HIGHER VINCRISTINE DOSES CORRELATE WITH LONGER OVERALL SURVIVAL: A POST-HOC ANALYSIS OF PARTICIPANTS RECEIVING PCV ON RTOG 9402
Donovan, Laura , Polly, Mei-Yin, Cairncross, J. Gregory , Lassman, Andrew B. , Souhami, Luís, Pitot, Henry C., Fisher, Barbara, Werner‐Wasik, Maria, Bahary, Jean-Paul , Whitton, Anthony , Hartford, Alan C. , Fink, Karen, Won, Minhee , IWAMOTO, FABIO MASSAITI , Barani, Igor J. , Mishra, Mark V. , Huang, Jiayi , Laperrière, Normand , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v252-v252

10.1093/neuonc/noad179.0970 Get It

Abstract RTOG 9402 demonstrated procarbazine (P), lomustine (CCNU/C), and vincristine (V), collectively PCV, added to radiation therapy significantly improved survival for patients with newly diagnosed anaplastic oligodendroglial tumors. The improvement was most pronounced in 1p19q codeleted cases, and to a lesser extent, IDH-mutant cases, with no survival benefit in cases with neither biomarker. Analogous results were observed in other phase III trials. However, vincristine (V) can cause substantial toxicity and requires intravenous administration, both negatively affecting quality of life, with debatable contribution to PCV efficacy. As a randomized trial comparing PCV to PC is unlikely to be conducted, we explored correlations between survival and V-dosing in patients randomized to PCV in RTOG 9402. We performed post-hoc analyses of all evaluable participants (n = 143) randomized to PCV on RTOG 9402, supplemented by restricting the analyses to the chemosensitive molecular subsets (IDH-mutant and/or 1p/19q codeleted, n = 118). Total V dose by quartile (Q) was calculated. Survival from six months post-randomization was compared among V dose groups, adjusting for age, extent of resection (EOR), and Karnofsky Performances Status (KPS) in a Cox proportional hazards model. Higher V dose received correlated with longer survival in multivariate analyses (n = 134, median-Q3 vs. < Q1, HR 0.40 (0.22, 0.73), p = 0.003; ≥Q3 vs. < Q1, HR 0.39 (0.22, 0.72), p = 0.002). Excluding chemoresistant cases (IDH wild-type/not codeleted), survival was also significantly longer in evaluable participants receiving the highest doses of vincristine (≥Q3 vs. < Q1 HR 0.42 (0.21,0.81), p = 0.01). In this post-hoc analysis, higher overall V-dose received correlated with longer survival in evaluable patients with anaplastic oligodendroglial tumors receiving PCV chemotherapy in RTOG 9402. Of note, as vincristine dosing was not assigned by randomization, confounding due to differences in patient characteristics among V dose groups cannot be ruled out. Caution should be exercised when considering discarding V from the PCV regimen.
RTID-06. THE PIVOTAL METIS (EF-25) STUDY OF TUMOR TREATING FIELDS (TTFIELDS) THERAPY FOR BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING RADIOSURGERY
Brown, Paul D. , Mehta, Minesh P. , Harat, Maciej , Roberge, David , Ahluwalia, Manmeet S.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v259-v260

10.1093/neuonc/noad179.0997 Get It

Abstract INTRODUCTION: TTFields are electric fields that disrupt processes necessary for cancer cell survival and can stimulate an antitumor immune response in preclinical NSCLC models. TTFields therapy is a noninvasive and locoregional treatment approved for glioblastoma, which has recently demonstrated a survival benefit when applied to the thorax with standard of care (SOC) systemic therapy in patients with metastatic NSCLC that progressed on/after platinum. Here we describe the pivotal METIS study (EF-25, NCT02831959) evaluating the efficacy and safety of TTFields therapy applied to brain metastases from NSCLC. TRIAL DESIGN: Patients (270) with 1–10 brain metastases from NSCLC will receive stereotactic radiosurgery (SRS), followed by 1:1 randomization to TTFields (NovoTTF-200M [150 kHz] applied to the head ≥ 18 h/day) with best SOC, or best SOC alone. Key inclusion criteria are life expectancy ≥ 3 months, a new diagnosis of 1 inoperable or 2–10 supra and/or infratentorial brain metastases from NSCLC, that are amenable to SRS. Patients who had prior whole brain radiotherapy, or have single operable, leptomeningeal, or recurrent brain metastases, certain genetic mutations, or severe comorbidities or contraindications, are not eligible. The primary endpoint is time to first intracranial progression. Secondary endpoints include time to neurocognitive failure, overall survival, radiological response rate, time to second intracranial progression, time to first/second intracranial progression by modified RECIST v1.1, rate of intracranial progression, time to distant progression, rate of cognitive decline, quality of life, neurocognitive failure-free survival, and safety. The study is powered at 80% (2-sided alpha of 0.05) to detect a hazard ratio of 0.57. In July 2021, an independent Data Monitoring Committee reviewed the study data and recommended continuation. The study includes 128 sites in Europe, Israel, mainland China, North America, and Hong Kong. The final patient was enrolled in March 2023.
STEM-20. REGULATION OF GLIOMA STEM CELL MAINTENANCE AND THERAPEUTIC RESISTANCE BY EGFR MISSENSE MUTATIONS
Weaver, Sidney , Miller, Aunay , Blomquist, Mylan, McNamara, James, Orndorff, Keely, Kloss, Jean , Sereduk, Christopher, Loftus, Joseph C. , Mehta, Shwetal , Sereduk, Chris , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v37-v37

10.1093/neuonc/noad179.0145 Get It

Abstract Glioblastoma (GBM) tumors contain a subpopulation of glioma stem cells (GSC) which can escape therapeutic effects through self-renewal and invasion. Epidermal growth factor receptor (EGFR) mutations are the most common alteration in GBM. EGFRvIII (deletion of exons 2-7) is observed in GBM (20-25%) resulting in a constitutively activated EGFR receptor. In addition, extracellular domain missense point mutations, (e.g. G598V, A289V, R108K) are observed in GBM (14.4%). These missense mutations in the EGFR extracellular domain also induces a highly active receptor by enhancing ligand binding. Earlier reports have shown that these EGFR missense point mutations have exhibited therapeutic resistance; however, the molecular mechanism of these missense point mutations in GBM remains unknown. Previous studies in our lab showed that EGFRvIII promotes GSC maintenance and therapeutic resistance via oligodendrocyte transcription factor 2 (OLIG2) signaling. OLIG2 is universally expressed in glioma and essential for reprogramming GBM cells into stem-like tumor cells. Increased OLIG2 expression promotes invasion, growth, proliferation, and survival. Here we report an increase in OLIG2 protein expression in GSCs harboring EGFR-G598V or EGFR-A289V mutations, suggesting these mutations may support stemness properties in GBM tumors. GSC expressing these point mutations display increased self-renewal, growth, and survival. In addition, EGFR-G598V and EGFR-A289V trigger distinct downstream signaling pathways in GSCs to regulate OLIG2 function. Hence, we hypothesize that GBM tumors harboring EGFR missense mutations (G598V, A289V) influence stem cell properties via multiple pathways to evade therapeutic effects and inhibiting these different signaling pathways will decrease therapeutic resistance in GBM. Understanding the mechanism of these EGFR mutations may lead to improved therapeutic strategies for GBM patients.